Chi, K.N.N.

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 167

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Sartor, O., Castellano Gauna, D. E., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N. N., Crosby, M., Piulats Rodriguez, J. M., Flechon, A., Wei, X. X., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 71

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Chi, K. N. N., Castro, E., Attard, G., Smith, M. R., Sandhu, S. K., Efstathiou, E., Roubaud, G., Small, E. J. J., Gomes, A. J. P. D. S., Rathkopf, D., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 12